Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.

NCT Number	NCT07697274
Lead Sponsor	Medical University of South Carolina
Conditions	Systemic Sclerosis, Sclerodactyly
Enrollment	10 participants
Start Date	2026-09-01
Primary Completion	2027-09 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-13